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O B J E C T I V E S The purpose of this study was to evaluate the effect of statin treatment on coronary
plaque composition and morphology by optical coherence tomography (OCT), grayscale and integrated
backscatter (IB) intravascular ultrasound (IVUS) imaging.
B A C KG ROUND Although previous studies have demonstrated that statins substantially improve cardiac
mortality, their precise effect on the lipid content and ﬁbrous cap thickness of atherosclerotic coronary lesions is
less clear. While IVUS lacks the spatial resolution to accurately assess ﬁbrous cap thickness, OCT lacks the
penetration of IVUS. We used a combination of OCT, grayscale and IB-IVUS to comprehensively assess the impact
of pitavastatin on plaque characteristics.
METHOD S Prospective serial OCT, grayscale and IB-IVUS of nontarget lesions was performed in 42
stable angina patients undergoing elective coronary intervention. Of these, 26 received 4 mg pitavastatin
after the baseline study; 16 subjects who refused statin treatment were followed with dietary modiﬁcation
alone. Follow-up imaging was performed after a median interval of 9 months.
R E S U L T S Grayscale IVUS revealed that in the statin-treated patients, percent plaque volume index was
signiﬁcantly reduced over time (48.5  10.4%, 42.0  11.1%; p  0.033), whereas no change was observed
in the diet-only patients (48.7 10.4%, 50.4 11.8%; p NS). IB-IVUS identiﬁed signiﬁcant reductions in the
percentage lipid volume index over time (34.9  12.2%, 28.2  7.5%; p  0.020); no change was observed
in the diet-treated group (31.0  10.7%, 33.8  12.4%; p  NS). While OCT demonstrated a signiﬁcant
increase in ﬁbrous cap thickness (140 42 m, 189 46 m; p 0.001), such changes were not observed
in the diet-only group (140 35 m, 142 36 m; p NS). Differences in the changes in the percentage lipid
volume index (6.8 8.0% vs. 2.8  9.9%, p  0.031) and ﬁbrous cap thickness (52 32 m vs. 2 22 m,
p  0.001) over time between the pitavastatin and diet groups were highly signiﬁcant.
CONC L U S I O N S Statin treatment induces favorable plaque morphologic changes with an increase
in ﬁbrous cap thickness, and decreases in both percentage plaque and lipid volume indexes. (J Am Coll
Cardiol Img 2012;5:169–77) © 2012 by the American College of Cardiology Foundation
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VVI vessel volume index
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he clinical benefit of lipid-lowering therapy
with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors has been conclusively
demonstrated by numerous large-scale, multi-
enter, randomized primary and secondary preven-
ion clinical trials (1–5). Numerous grayscale intra-
ascular ultrasound (IVUS) imaging studies have
evealed that statins blunt the progression of
therosclerosis or even decrease the percentage
f atheroma volume (6–11). However, radio-
requency analysis with integrated backscatter–
See page 178
IVUS (IB-IVUS) has demonstrated a substantial
decrease in the lipid burden and an increase in the
fibrous content of a plaque in response to
statins (12,13). Although the lipid fraction
of a plaque and the plaque volume are
determinants of plaque instability, the
presence of a thin fibrous cap is the hall-
mark of a high-risk plaque (14–19). IVUS
lacks the spatial resolution to accurately
assess small changes in fibrous cap thick-
ness. On the other hand, a single study
using optical coherence tomography
(OCT) demonstrated that statin therapy
after the onset of acute myocardial infarc-
tion resulted in an increase in fibrous cap
thickness (20). OCT, however, lacks the
penetration of IVUS, and it is conceivable
that a combination of IVUS and OCT
would offer a comprehensive account of
alterations in plaque morphology in re-
sponse to statin treatment.
METHODS
Study design and patient selection. This nonran-
domized, case-control study prospectively enrolled
42 patients with stable angina undergoing elective
percutaneous coronary intervention (PCI) to eval-
uate the effects of statin therapy on nontarget
lesions. Of these, 26 received pitavastatin 4 mg/day
and 16 who declined any form of lipid-lowering
pharmacotherapy received dietary intervention
alone. The low-density lipoprotein cholesterol
(LDL-C)–lowering efficacy of pitavastatin is com-
parable to that of atorvastatin (8). Serial imaging
was performed in nontarget lesions, first during
PCI and subsequently after a median duration of 9
months. Discrete nonobstructive lesions (50%
tein
y
ystenosis by quantitative coronary angiography),identified by angiography, IVUS, and OCT, 5
mm proximal or distal to the stented lesions that
were not in tandem or diffuse were studied. All
patients underwent grayscale and IB-IVUS as well
as OCT imaging. Patients already established on
lipid-lowering therapy and those with contraindi-
cations to repeat coronary angiography and intra-
coronary imaging were excluded. The study was
approved by our institutional ethics committee, and
all patients gave written informed consent.
Angiographic and intracoronary imaging procedures.
A 7-F guiding catheter was introduced via the
femoral approach after administration of 100
IU/kg intravenous heparin. Selective coronary
angiography was performed after the intracoro-
nary injection of nitrates. All the lesions were
treated with stent implantation after which im-
aging procedures were performed. The tech-
niques and devices used for PCI were left to the
operator’s discretion.
After the passage of a 0.014-inch guidewire
across the lesion, the proximal occlusion balloon
catheter was positioned proximal to the lesion and a
0.014-inch guidewire was removed and exchanged
for a 0.016-inch OCT image wire (LightLab Im-
aging, Westford, Massachusetts) (21,22). After the
careful passage of a 0.016-inch OCT image wire
through the lesion, a proximal occlusion balloon
catheter was inflated, and then lactated Ringer’s
solution was continuously flushed through the lumen
to remove blood flow. Motorized pull-back was
started at a rate of 1.0 mm/s for a length of 30 mm.
Non–PCI-related plaques (at least 5 mm proximal or
distal to the PCI site) with readily identifiable nearby
landmarks to facilitate serial imaging were studied.
The images were saved in the OCT image system
digitally for subsequent analysis (18,22–26). After
OCT, a mechanical IVUS imaging catheter (40
MHz, 2.5-F, Boston Scientific, Natick, Massachu-
setts) was introduced over a 0.014-inch guidewire
and positioned distal to the lesion (8,27,28).
Lesion geometry was then imaged by using mo-
torized pull-back (0.5 mm/s). For IB-IVUS im-
age acquisition, a personal computer equipped
with custom software (IB-IVUS, YD Co. Ltd.,
Nara, Japan) was connected to the IVUS imaging
system (ClearView, Boston Scientific) to obtain
radiofrequency signal output, signal trigger out-
put, and video image output. IVUS images and
data were stored electronically for offline analysis.
Image analysis. Intracoronary image analysis wasA B B R E V I A T I O N S
A N D A C R O N YM S
IB-IVUS integrated
backscatter–intravascular
ultrasound
LA lumen area
LDL-C low-density lipopro
cholesterol
LVI lumen volume index
OCT optical coherence
tomography
PCI percutaneous coronar
intervention
PLA plaque area
PVI plaque volume index
QCA quantitative coronar
angiography
VA vessel areaperformed by the consensus of 3 experienced
eren
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 2 , 2 0 1 2
F E B R U A R Y 2 0 1 2 : 1 6 9 – 7 7
Hattori et al.
Impact of Statin Therapy on Plaque Characteristics
171blinded observers (Y.O., M.O., K.H.) with no
access to clinical records during assessment (Fig. 1).
In OCT images, fibrous cap thickness was assessed
(19,20,22). IVUS-verified cross-sectional lumen
area was defined as the integrated area central to the
Figure 1. Coronary Angiographic, Grayscale IVUS, IB-IVUS, and
While no signiﬁcant difference was found between baseline and follow
slice) decreased from 12.9 mm2 to 12.1 mm2 by grayscale IVUS during
to 30.0%, while ﬁbrous (green) volume index increased from 52.1% to
ness increased from 80 m to 220 m during follow-up (arrows in A4
IVUS  intravascular ultrasound; LA  lumen area; OCT  optical coh
Figure 2. Coronary Angiographic, Grayscale IVUS, IB-IVUS, and
Whilst signiﬁcant progression was observed by angiography during follow
increased from 18.2 to 20.0 mm2 by grayscale IVUS during follow-up (C2
ﬁbrous (green) volume index decreased from 66.2% to 60.0% by IB-IVUS
change during follow-up (arrows in C4 and D4). Abbreviations as in Figure 1.intimal leading edge echo (27,28). The total vessel
cross-sectional area was defined as the area inside
the interface between the plaque-media complex
and adventitia (27,28). The plaque area was defined
as the vessel area minus the lumen area. Vascular
at Baseline and Follow-Up for the Pitavastatin Group
angiography (A1, B1), plaque volume index (i.e., plaque area in this
ow-up (A2 and B2). Lipid (blue) volume index decreased from 45.9%
% by IB-IVUS (A3 and B3). OCT revealed that the ﬁbrous cap thick-
d B4). IB-IVUS  integrated backscatter–intravascular ultrasound;
ce tomography; PLA  plaque area; VA  vessel area.
at Baseline and Follow-Up for the Dietary Group
(C1 and C2), plaque volume index (e.g., plaque area in this slice)
D2). Lipid (blue) volume index increased from 32.1% to 37.9%, whereas
nd D3). OCT revealed that the ﬁbrous cap thickness of 110 m did notOCT
-up
foll
65.6
anOCT
-up
and
(C3 a
revascularization.
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172volume and lumen volumes were then calculated
using Simpson’s rule. The plaque volume was cal-
culated by subtracting the lumen volume from the
vascular volume. All values were indexed for lesion
Demographic and Clinical Characteristics
Pitavastatin Diet therapy p Value
26 16 —
26 16 —
66 7.8 68 6.2 0.194
25 (96.1) 13 (81.3) 0.110
months 9.0 (8.0–9.0) 9.0 (7.5–9.6) 0.641
9 (34.6) 4 (25.0) 0.513
6.0 1.0 5.7 0.9 0.229
Hg 13 (50.0) 9 (56.3) 0.694
129 17 140 20 0.061
74 10 78 13 0.313
121 15 128 13 0.104
p 69 13 76 9 0.067
12 (46.2) 5 (31.2) 0.339
7 (26.9) 4 (25.0) 0.891
7 (26.9) 7 (43.8) 0.261
p 3 (11.5) 4 (25.0) 0.256
ow-up 4 (15.4) 3 (18.8) 0.776
l
l 197 46 200 40 0.806
134 40 122 25 0.305
46 11 59 16 0.005
tio 3.08 1.16 2.20 0.65 0.009
147 48 117 69 0.094
24 (92.3) 13 (81.2) 0.282
2 (7.7) 3 (18.8) 0.282
low-up/after index PCI
26/26 (100) 16/16 (100) 1.000
9/9 (100) 6/7 (85.7) 0.241
13/14 (92.8) 7/9 (77.8) 0.294
12/12 (100) 11/11 (100) 1.000
18/18 (100) 7/7 (100) 1.000
9/10 (90) 2/2 (100) 0.640
iac events
0 (0) 0 (0) 1.000
0 (0) 0 (0) 1.000
4 (15.4) 2 (12.5) 0.795
4 (15.4) 2 (12.5) 0.795
4 (15.4) 3 (18.8) 0.776
0 (0) 0 (0) 1.000
D, n (%), median (interquartile range), or n/N (%).
converting enzyme inhibitor; ARB angiotensin II receptor blocker; BMS bare
oronary artery bypass grafting; CCB calcium channel blocker; DBP diastolic
 drug-eluting stent; HDL-C  high-density lipoprotein cholesterol; LDL-C 
in cholesterol; MI  myocardial infarction; PCI  percutaneous coronary
stolic blood pressure; TLR target lesion revascularization; TVR target vesselflength to give the vascular volume index, lumen
volume index, and plaque volume index.
Integrated backscatter values for each tissue com-
ponent were calculated as an average power using a
fast Fourier transform of the frequency component
of backscattered signal from a small volume of
tissue (12,13). The percentage of fibrous volume
(fibrous volume/plaque volume) and the percentage
of lipid volume (lipid volume/plaque volume) were
automatically calculated by the IB-IVUS system.
The percentage of the high-signal volume (a part of
the calcification on the inner surface that could be
measured with the formula of IB-IVUS/plaque vol-
ume) was also automatically calculated by IB-IVUS as
a high-signal volume (12,29,30). The percentage fi-
brous volume, the percentage lipid volume, and the
high-signal volume were calculated using Simpson’s
rule. All values were indexed for lesion length to give
the percentage fibrous volume index, the percentage
lipid volume index, and the percentage high-signal
volume index.
Statistical analysis. Data were analyzed using the
SAS statistical software package version 9.1 (SAS
Institute, Cary, North Carolina). All continuous
values are expressed as mean  SD for normally
distributed variables and median  interquartile
range for nonparametric data. The Kolmogorov-
Smirnov test was used to assess the normality of
continuous data. Differences in categorical variables
were assessed using the chi-square test and Fisher
exact test as appropriate. Differences between
paired continuous data were assessed using the
paired Student t test. Between-group comparisons
were made using the independent-samples t test or
Mann-Whitney U test as appropriate. We used
linear regression analysis to assess relationships
between the percentage change in LDL-C during
follow-up and several factors, including the per-
centage change in the coronary plaque volume index
by grayscale IVUS, the percentage change in the
lipid volume index by IB-IVUS, the percentage
change in the fibrous volume index by IB-IVUS,
and the percentage change in fibrous cap thickness
by OCT. Analysis of covariance was used to adjust
for differences in baseline lipid profiles between
groups. Two-tailed p values 0.05 were considered
significant.
RE SULTS
Clinical characteristics. Serial intracoronary imagingTable 1. Baseline
No. of patients
No. of lesions
Age, yrs
Male
Follow-up period,
Diabetes
HbA1C level, %
Hypertension, mm
SBP
DBP
SBP at follow-up
DBP at follow-u
Smoking
Nonsmoker
Ex-smoker
Current smoker
Quit at follow-u
Contined at foll
Lipid proﬁle, mg/d
Total cholestero
LDL-C
HDL-C
LDL-C/HDL-C ra
Triglycerides
Stent type
DES
BMS
Medications at fol
Aspirin
Clopidogrel
Ticlopidine
Beta-blocker
ARB or ACEI
CCB
Major adverse card
Death
MI
Restenosis rate
TLR
TVR
CABG
Values are mean  S
ACEI angiotensin-
metal stent; CABG c
blood pressure; DES
low-density lipoprote
intervention; SBP syollow-up was performed at a median duration of
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1739.0 months (interquartile range, 7.8 to 9.0 months)
in all 42 patients. The baseline clinical and demo-
graphic characteristics of the treatment and control
groups are summarized in Table 1. Both groups
were comparable with respect to baseline character-
istics, except for the presence of a higher high-
density lipoprotein cholesterol level and subse-
quently lower LDL-C/high-density lipoprotein
cholesterol ratio in the dietary treatment group. Of
the 26 patients in the pitavastatin arm, 24 (92%)
underwent PCI with drug-eluting stents and 2 (8%)
received bare metal stents. Of the 16 patients with
diet modification, 13 (81%) received drug-eluting
stents and the remaining 3 (19%) received bare
metal stents; there was no difference in the use of
drug-eluting stent or bare metal stent implantation
between the 2 groups (p  0.282) (Table 1). A
comparable number of patients in both groups
experienced restenosis: 4 (15.4%) in the pitavastatin
group and 2 (12.5%) in the diet-only group (p 
0.795). All 6 of these patients underwent repeat
PCI of restenotic lesions; therefore, the target
lesion revascularization rate was comparable in both
groups. One patient in the diet-only group had a
new significant lesion proximal to the original target
lesion necessitating PCI. Therefore, target vessel
revascularization including target lesion revascular-
ization was needed in 4 patients (15.4%) in the
pitavastatin group and 3 patients (18.7%) in the
diet-only group (p  0.776).
Lesion characteristics. Baseline lesion dimensions
assessed by grayscale IVUS) and plaque composi-
ion (assessed by IB-IVUS) were comparable for the
groups (Table 2). Fibrous cap thickness in both
roups was also similar. In the treatment arm,
itavastatin resulted in significant reductions in
otal cholesterol, LDL-C as well as a significant
ncrease in high-density lipoprotein cholesterol, but
here was no appreciable change in triglyceride
evels (Table 3). In comparison, in the dietary
herapy control arm, there was no significant
hange in any component of the lipid profile be-
ween baseline and follow-up (Table 3).
Lipid-lowering therapy was associated with a
ignificant decrease in the percentage plaque vol-
me index by grayscale IVUS and the percentage
laque lipid area by IB-IVUS (Table 3). The
ercentage plaque volume index was reduced from
8.5 10.4% to 42.0 11.1% (p 0.05) over time
in the statin-treated arm; no change was observed in
the diet-only patients (48.7  10.4%, 50.4 
11.8%; p  NS). IB-IVUS revealed a significant pdecrease in the percentage lipid volume index from
34.9 12.2% to 28.2 7.5% (p 0.05) over time;
no change was apparent in the diet-only group
(31.0  10.7% and 33.8  12.4%; p  NS).
Although OCT demonstrated a significant increase in
fibrous cap thickness (140  42 m and 189  46
m; p  0.001), such changes were not observed in
the diet-only group (140  35 m and 142  36
m; p  NS). Differences in the changes in the
percentage lipid volume index from6.8 8.0% to
2.8  9.9% (p  0.03) and fibrous cap thickness
rom 52  32 m to 2  22 m (p  0.001)
etween the pitavastatin and diet-only groups on serial
ollow-up were highly significant (Figs. 1 and 2).
We also examined the correlation between the
ercentage change in LDL-C and the change in
everal parameters. Figure 3 indicates that the
ercentage change in LDL-C had a significant
ositive correlation with the percentage change in
he plaque volume index by grayscale IVUS (r 
.39, p  0.011) and with the percentage change in
he lipid volume index by IB-IVUS (r  0.40, p 
.008). The percentage change in LDL-C also
howed a significant negative correlation with the
ercentage change in the fibrous volume index by
B-IVUS (r  0.38, p  0.013) and the percent-
ge change in fibrous cap thickness byOCT (r0.40,
Table 2. Baseline Intracoronary Imaging Data
Baseline Pitavastatin Diet Therapy
Target plaque location
LAD 15 (57.7) 5 (31.3)
LCx 0 (0.0) 2 (12.5)
RCA 11 (42.3) 9 (56.3)
IVUS measurements,
mm3/mm
VVI 16.8 4.1 17.6 5.6
LVI 8.7 2.8 9.2 3.8
PVI 8.1 2.4 8.5 2.9
% PVI, % 48.5 10.4 48.7 10.4
Lesion length, mm 6.4 2.6 6.1 2.8
IB-IVUS analysis, %
Lipid volume index 34.9 12.2 31.0 10.7
Fibrous volume
index
63.9 11.7 67.2 9.5
OCT measurements
Fibrous cap
thickness, m
140 42 140 35
Values are n (%) or mean  SD.
IB-IVUS  integrated backscatter intravascular ultrasound; IVUS  intravascular
LAD  left anterior descending coronary artery; LCx  left circumﬂex coronary a
lumen volume index; OCT  optical coherence tomography; PVI  plaque vo
%PVI  plaque volume index divided by vascular volume index; RCA  right coro
VVI  vascular volume index.p Value
0.078
—
—
0.559
0.631
0.639
0.963
0.762
0.298
0.348
0.997
ultrasound;
rtery; LVI 
lume index;
nary artery; 0.010).
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174DI SCUSS ION
Plaque regression and stabilization are expected to
be the key mechanisms underlying the clinical
benefit of lipid-lowering therapy with statins.
Plaques susceptible to rupture are characterized by
thin fibrous caps and a high lipid burden (31–33).
Previous studies using grayscale IVUS demon-
strated that significant reductions in plaque volume
occur even after relatively short periods of therapy
with different statins. On the other hand, radiofre-
quency IVUS analyses have confirmed that statins
induce favorable changes in the plaque composition
with a decrease in the lipid volume and an increase
in the fibrous content (12,30). In the present study,
we observed a significant correlation between
LDL-C and a reduction in plaque and lipid volume.
However, there was a significant negative correla-
tion between the percentage decrease inLDL-Cand the
percentage increase in the fibrous volume and the per-
centage increase in fibrous cap thickness.
The magnitude of the decrease in the plaque
volume index with pitavastatin in our study (6.5 
.2%) was similar to that in the JAPAN-ACS
Japanese Assessment of Pitavastatin and Atorvas-
atin in Acute Coronary Syndrome) study (5.7 
.3%) (8) and to the increase in the fibrous cap
es in Lipid Proﬁle, Grayscale IVUS, IB-IVUS, and OCT Findings
Pitavastatin Diet Therapy
Baseline Follow-Up p Value Baseline Follow-Up p
197 46 164 24 0.002 200 40 195 33
134 40 89 23 0.001 122 25 121 30
46 11 58 16 0.004 59 16 53 14
3.08 1.16 1.67 0.61 0.001 2.20 0.65 2.41 0.82
147 48 137 82 0.569 117 69 129 71
16.8 4.1 15.9 4.1 0.483 17.6 5.6 17.4 6.0
8.7 2.8 9.3 3.0 0.469 9.2 3.8 9.4 5.6
8.1 2.4 6.7 2.5 0.050 8.5 2.9 8.9 3.8
48.5 10.4 42.0 11.1 0.033 48.7 10.4 50.4 11.8
34.9 12.2 28.2 7.5 0.020 31.0 10.7 33.8 12.4
63.9 11.7 70.0 7.4 0.029 67.2 9.5 64.1 11.6
140 42 189 46 0.001 140 35 142 36
alue at follow-up minus value at baseline. †p Value adjusted for differences in b
2.hickness seen in a recent OCT study (20) of acuteyocardial infarction patients. Our study had the
istinct advantage of using both IB-IVUS and
CT imaging modalities for better plaque charac-
erization and the same statin at a consistent dose of
mg pitavastatin to minimize the possibility of
arying responses to different statins of different
otency and dose. We also managed to obtain
omplete imaging follow-up in all patients at 9
onths after treatment.
The use of OCT to assess fibrous cap thickness is
uperior to IVUS because the spatial resolution of
VUS is only 100 m, and vulnerable fibrous caps
are typically 65 m thick (34,35). IVUS is there-
fore unable to resolve small changes in fibrous cap
thickness. Our data suggest that statins confer a
beneficial increase in fibrous cap thickness. This
provides valuable mechanistic insights into the po-
tentially beneficial effects of statins, which could be
used to benchmark future investigational agents
that target plaque instability. This finding seems to
support data from a previous study using CT
angiography that demonstrated a substantial de-
crease in plaque volume in response to statin ther-
apy (36). This preliminary study suggested that
even low-dose statin use resulted in significant
changes in plaque morphology. Statin treatment
Pitavastatin*
Diet
Therapy*
p
Value†ue
0 Change in total
cholesterol
32.7 43 5.4 49 0.026
9 Change in LDL-C 44.5 30 0.6 34 0.001
1 Change in HDL-C 11.6 13 5.1 9 0.001
2 Change in LDL-C/HDL-C 1.41 0.76 0.21 0.71 0.001
0 Change in triglycerides 10.7 70 12.8 107 0.422
5 Change in VVI 0.8 1.7 0.3 1.9 0.185
5 Change in LVI 0.6 1.4 0.2 3.2 0.746
0 Change in PVI 1.4 1.2 0.4 1.5 0.001
0 Change in %PVI 6.5 6.2 1.7 5.6 0.001
6 Change in percentage
lipid volume index
6.8 8.0 2.8 9.9 0.031
9 Change in percentage
ﬁbrous volume index
6.1 7.3 3.1 9.2 0.014
1 Change in thickness 52 32 2 22 0.001
e HDL-C.Table 3. Serial Chang
Val
Lipid proﬁle, mg/dl
Total cholesterol 0.68
LDL-C 0.94
HDL-C 0.33
LDL-C/HDL-C ratio 0.42
Triglycerides 0.61
IVUS measurements,
mm3/mm
VVI 0.90
LVI 0.90
PVI 0.74
% PVI, % 0.67
IB-IVUS analysis, %
Lipid volume index 0.50
Fibrous volume
index
0.41
OCT measurements
Fibrous cap
thickness, m
0.86
Values are mean  SD. *V aselinresulted in significant reduction of low attenuation
revia
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175plaque volume (IVUS equivalent of necrotic core
component in computed tomography angiography)
and in turn an absolute decrease in plaque volume.
These changes in low attenuation and total plaque
volume occurred when no significant change was
observed in the lumen size, even if the changes in the
lipid profile were not substantial. Somewhat similar
results were reported from 18-fluorodeoxyglucose im-
aging of the carotid vasculature, which showed signif-
icant resolution of plaque inflammation in response to
statin therapy; plaque inflammation remained un-
changed after dietary intervention (37,38). Fibrous cap
reinforcement and resolution of inflammation could
be interrelated through cytokine and metalloprotei-
nase attenuation, which is also known to be associated
with statin therapy (39).
Study limitations. First, the number of patients
studied is relatively small; however, this reflects the
cost and logistical difficulties inherent in perform-
ing multimodality invasive intracoronary imaging.
Second, given the established clinical benefit of
lipid-lowering therapy, it would have been unethi-
cal to withhold treatment from the control group or to
Figure 3. Relationship Between the Percentage of Change in LD
Relationship between percentage change in LDL-C and percentage
change in the lipid volume index by IB-IVUS (B), percent change in
ﬁbrous cap thickness by OCT (D). Signiﬁcant modest correlation wa
parameters. LDL-C  low-density lipoprotein cholesterol; other abbuse a crossover design. We therefore relied on patientswho could not tolerate or had declined lipid-lowering
therapy for our control group, raising the possibility of
selection bias. Another possible study design could have
used 2 different doses of same statins or 2 different statins
for comparison of the efficacy of intervention on plaque
instability. Nevertheless, the treatment and control
groups in our study were very comparable with respect
to important baseline clinical and lesion characteris-
tics. Finally, over the short duration of this study, it
was not possible to assess the significance of these
changes with respect to event-driven, hard clinical
endpoints. Nevertheless, such changes seen in the
lipid profile have been previously established to trans-
late into substantial decreases in clinical events with
drugs in this class, and in this regard, pitavastatin has
been shown to be noninferior to older statins.
CONCLUS IONS
Treatment with pitavastatin in patients with stable
angina induces significant plaque regression and, by
decreasing plaque lipid content and increasing plaque
fibrous cap thickness, induces plaque stabilization.
and Percentage of Grayscale IB-IVUS, and OCT Parameters
nge in plaque volume index by grayscale IVUS (A), percentage
ﬁbrous volume index by IB-IVUS (C), and percentage change in
served between the percentage change in LDL-C and all 4
tions as in Figure 1.L-C
cha
the
s obThe use of serial multimodality intracoronary imaging
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176provides significant insights into the mechanisms
underlying the clinical benefits of statins. Further
work is required to prospectively correlate these
changes with long-term clinical outcomes.
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